Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
Samuel LévyJuha HartikainenBeate RitzTord JuhlinJosé Carbajosa-DalmauHans DomanovitsPublished in: Cardiovascular drugs and therapy (2020)
This large multicenter, international observational study confirms the good safety profile and the high effectiveness of vernakalant for the rapid cardioversion of recent-onset AF in daily hospital practice.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- catheter ablation
- left atrial
- healthcare
- left atrial appendage
- direct oral anticoagulants
- heart failure
- randomized controlled trial
- systematic review
- loop mediated isothermal amplification
- percutaneous coronary intervention
- emergency department
- coronary artery disease
- double blind
- acute coronary syndrome